Lung Cancer Clinical Trials

Find Lung Cancer Clinical Trials Near You

Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Video assisted pulmonary resection, pleurodesis or decortication

Locations
United States
Washington, D.c.
The George Washington University Hospital
RECRUITING
Washington D.c.
Contact Information
Primary
Eduard Shaykhinurov, MS
eshaykhinurov@mfa.gwu.edu
2022038960
Time Frame
Start Date: 2025-03-01
Estimated Completion Date: 2029-02-28
Participants
Target number of participants: 120
Treatments
Active_comparator: Preoperative Erector Spinae Block (ESB)(Bupivacaine)(Marcaine®)
Active_comparator: Intraoperative Intercostal Nerve Block (INB)(Liposomal Bupivacaine)(Exparel®)
Related Therapeutic Areas
Lung Cancer
Acute Pain
Sponsors
Leads: George Washington University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)

A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)

Who is this study for: Adult patients with non-small cell lung cancer
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Drug
Study Drugs: Coformulation pembrolizumab/Quavonlimab, Lenvatinib, MK-4830, Coformulation favezelimab/Pembrolizumab
Study Phase: Phase 1/Phase 2

Safety, Tolerability, and Efficacy of SHR-A2102 in Combination With Adebrelimab, With SHR-8068, in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase IB/II Open-Label, Multicenter Clinical Study

Safety, Tolerability, and Efficacy of SHR-A2102 in Combination With Adebrelimab, With SHR-8068, in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase IB/II Open-Label, Multicenter Clinical Study

Enrollment Status: Recruiting
Publish Date: November 12, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

A Randomized Phase II Study of LAZE Rti N ib Alone Versus Lazertinib Plus Beva C Izumab for A Dvanced Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations and Smoking History

A Randomized Phase II Study of LAZE Rti N ib Alone Versus Lazertinib Plus Beva C Izumab for A Dvanced Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations and Smoking History

Enrollment Status: Recruiting
Publish Date: December 05, 2023
Intervention Type: Drug
Study Phase: Phase 2
View All